Pediatric Exclusivity Incentives Proposed In European Commission Draft Reg
This article was originally published in The Pink Sheet Daily
The lack of information on pediatric use of drugs remains a problem in Europe, EC's Brunet tells DIA EuroMeeting in Prague. A draft proposal would create a new marketing authorization system and provide data exclusivity to incentivize pediatric studies in off-patent drugs.
You may also be interested in...
The British regulatory agency’s proposal would offer scientific advice and waive fees for applications that include pediatric data in labeling. An EU-wide regulation on pediatric incentives is not expected before 2006.
Senior VP-Global Clinical & Pharmaceutical Development Elliott Sigal is acting president of Bristol-Myers Squibb’s research institute following the death of James Palmer.